Funding for this research was provided by:
NSW Ministry of Health (H13/115985-1)
Received: 14 October 2020
Accepted: 9 July 2021
First Online: 26 July 2021
: Ethics approval for this study was granted by South-East Sydney Local Health District Human Research Ethics Committee, reference number 15/030 (HREC/15/POWH/56).
: Not applicable.
: AJD has no conflicts of interest related to this project but reports grants from Braeburn/Camurus to conduct clinical studies with buprenorphine products and travel support to Hunter New England Local Health District, which employs AJD. He is also an investigator on an Indivior-funded study of buprenorphine products. AJD has serviced on an advisory board for Mundipharma.IM reports grants and salary support from NHMRC and grants from Lambert Initiative for Cannabinoid Therapeutics during the conduct of the study for projects unrelated to the submitted work; IM is also a consultant to Kinoxis Therapeutics and has received speaking fees from Janssen. He reports patents to WO2018107216A1, WO2017004674A1 and WO2011038451A1 issued and licensed, and patents to AU2017904438, AU2017904072, and AU2018901971 pending.NL has no conflicts of interest related to this project but has received research funding for unrelated research with Camurus and has also served on advisory boards for Indivior, Mundipharma and Camurus.All other authors have no competing interests to declare and have no support from any organisation or other relationships or activities that could appear to have influenced the submitted work.